Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BLRX 
BioLineRx Ltd (BLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: BLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.28% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.35M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 2 | Beta 0.91 | 52 Weeks Range 2.30 - 22.40 | Updated Date 10/21/2025 |
52 Weeks Range 2.30 - 22.40 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -45.34% | Operating Margin (TTM) -757.57% |
Management Effectiveness
Return on Assets (TTM) -15.36% | Return on Equity (TTM) -45.94% |
Valuation
Trailing PE - | Forward PE 93.46 | Enterprise Value 2173925 | Price to Sales(TTM) 0.95 |
Enterprise Value 2173925 | Price to Sales(TTM) 0.95 | ||
Enterprise Value to Revenue 0.13 | Enterprise Value to EBITDA 1.11 | Shares Outstanding 4262685 | Shares Floating 2453081621 |
Shares Outstanding 4262685 | Shares Floating 2453081621 | ||
Percent Insiders 4 | Percent Institutions 1.52 |
Upturn AI SWOT
BioLineRx Ltd
Company Overview
History and Background
BioLineRx Ltd. (BLRX) is a biopharmaceutical company focused on developing and commercializing novel therapeutics. Founded in 2003, it has evolved from a drug development company to a commercial-stage entity with a focus on hematology and oncology.
Core Business Areas
- Hematology/Oncology: Development and commercialization of therapies for hematological malignancies and solid tumors. This includes the FDA-approved product APHARDA (motixafortide) for stem cell mobilization in multiple myeloma patients.
Leadership and Structure
The leadership team includes experienced professionals in the biopharmaceutical industry. The organizational structure includes departments for R&D, clinical development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- APHARDA (motixafortide): APHARDA is used, in combination with filgrastim, to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma patients. Market share is nascent as of this analysis, pending further market penetration. Competitors include existing stem cell mobilization regimens, such as plerixafor (Mozobil) by Sanofi.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. Market dynamics are driven by innovation, unmet medical needs, and competitive pressures.
Positioning
BioLineRx is positioned as a company focused on innovative therapies for hematology and oncology. Its competitive advantage lies in its proprietary platform and its ability to develop and commercialize niche products.
Total Addressable Market (TAM)
The TAM for stem cell mobilization therapies is estimated to be several hundred million USD annually. BioLineRx is positioned to capture a share of this market with APHARDA.
Upturn SWOT Analysis
Strengths
- FDA-approved product (APHARDA)
- Proprietary technology platform
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on a single product for revenue
- Limited commercial infrastructure
- High R&D expenses
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Acquisition of complementary technologies
- Geographic expansion
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- SNY
Competitive Landscape
BioLineRx is a smaller player in the market compared to established pharmaceutical companies like Sanofi. Its advantage lies in its innovative approach, but it faces challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on the successful development and commercialization of its pipeline products.
Future Projections: Future growth is tied to the commercial success of APHARDA and the progress of its pipeline programs. Analyst estimates vary widely, reflecting the uncertainty of drug development.
Recent Initiatives: Recent initiatives include the commercial launch of APHARDA and the advancement of its pipeline programs.
Summary
BioLineRx is a developing pharmaceutical company that is just beginning to commercialize. Success or failure for the company will hinge greatly on APHARDA sales. The company is at a disadvantage compared to established players with more resources. The company should look for partnerships to off-set these costs. Investors should proceed cautiously due to reliance on a single new product.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLineRx Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2011-07-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.biolinerx.com |
Full time employees 28 | Website https://www.biolinerx.com | ||
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.